American Oncology Network (AON) announced that they have entered into a definitive business combination agreement and will become a public company.
Fort Myers, Fla. & Los Angeles, October 6, 2022 – American Oncology Network, LLC (AON) announced that they have entered into a definitive business combination agreement with Digital Transformation Opportunities Corp. (DTOC) pursuant to which AON will become a public company (the “Business Combination”).
Upon the closing of the Business Combination, AON’s senior leadership team will continue to serve in their current roles. The combined company will be led by AON’s chief executive officer (CEO) Todd Schonherz, President and chief development officer Brad Prechtl, chief financial officer David Gould, and chief medical officer Dr Stephen "Fred" Divers. AON’s existing board, which is composed of practicing medical oncologists, is expected to remain in place and will be joined by additional members affiliated with DTOC.
“This transaction represents the next step in AON’s journey to become the leading platform for community-based oncology practices. Since launching the AON platform in 2018, we’ve been able to drive consistently strong growth by providing our physician partners with a strong suite of practice management tools and ancillary services as well as access to the financial benefits associated with being integrated with a scaled platform," said AON CEO Todd Schonherz.
"We look forward to continuing to grow our network of physician partners and supporting them with our physician practice management platform.”
AI in Health Care: Balancing Governance, Innovation, and Trust
September 2nd 2025In this conversation with Reuben Daniel, associate vice president of artificial intelligence at UPMC Health Plan, we dive into how UPMC Health Plan builds trust with providers and members, discuss challenges of scaling AI effectively, and hear about concrete examples of AI's positive impact.
Listen
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More